Early postoperative levothyroxine initiation after total thyroidectomy for Graves’ disease

No evidence-based standards exist regarding levothyroxine (LT4) replacement therapy initiation timing in patients with hyperthyroid Graves’ disease undergoing total thyroidectomy. Although LT4 replacement from the first postoperative day has been the standard of care at our hospital, its clinical va...

Full description

Saved in:
Bibliographic Details
Published inEndocrine Journal Vol. 72; no. 7; pp. 813 - 818
Main Authors Nagayama, Yuji, Tachibana, Seigo, Fukuda, Takashi, Katsuyama, Kento, Tatsushima, Daisuke, Mori, Yusuke, Shindo, Hisakazu, Takahashi, Hiroshi, Okamura, Misa, Yamaoka, Atsushi, Sato, Shinya, Yamashita, Hiroyuki
Format Journal Article
LanguageEnglish
Published Japan The Japan Endocrine Society 01.01.2025
一般社団法人 日本内分泌学会
Japan Science and Technology Agency
Subjects
Online AccessGet full text
ISSN0918-8959
1348-4540
1348-4540
DOI10.1507/endocrj.EJ25-0009

Cover

Loading…
Abstract No evidence-based standards exist regarding levothyroxine (LT4) replacement therapy initiation timing in patients with hyperthyroid Graves’ disease undergoing total thyroidectomy. Although LT4 replacement from the first postoperative day has been the standard of care at our hospital, its clinical validity has not been thoroughly examined. This study investigated the perioperative kinetics of thyroid hormones to assess the safety and efficacy of early LT4 initiation. Thirty patients with Graves’ disease (18 hyperthyroid and 12 euthyroid) and 12 with thyroid nodules who underwent total thyroidectomy were included. Blood samples were collected from each patient for thyroid hormone measurement on the day before surgery (D-1), 15 min after surgery (D0), at 8:00 am on days 1 (D1) and 3 (D3), and 3 weeks (W3) and 3 months (M3) after surgery. In 18 patients with hyperthyroid Graves’ disease, serum free triiodothyronine (FT3) levels significantly decreased immediately after surgery and were within the normal range by D1. Although LT4 was started on D1, FT3 levels continued to decline by D3 and remained low at W3 and M3. Serum FT4 levels followed a slower decline but remained within the normal range for M3. In patients with euthyroid Graves’ disease and those with thyroid nodules, hormone levels stayed within or around the reference range throughout the observation period. In conclusion, initiating LT4 on the day after surgery is safe and effective for maintaining thyroid function in patients with hyperthyroid Graves’ disease undergoing total thyroidectomy. These results could inform future guidelines, supporting earlier postoperative LT4 initiation.
AbstractList No evidence-based standards exist regarding levothyroxine (LT4) replacement therapy initiation timing in patients with hyperthyroid Graves’ disease undergoing total thyroidectomy. Although LT4 replacement from the first postoperative day has been the standard of care at our hospital, its clinical validity has not been thoroughly examined. This study investigated the perioperative kinetics of thyroid hormones to assess the safety and efficacy of early LT4 initiation. Thirty patients with Graves’ disease (18 hyperthyroid and 12 euthyroid) and 12 with thyroid nodules who underwent total thyroidectomy were included. Blood samples were collected from each patient for thyroid hormone measurement on the day before surgery (D-1), 15 min after surgery (D0), at 8:00 am on days 1 (D1) and 3 (D3), and 3 weeks (W3) and 3 months (M3) after surgery. In 18 patients with hyperthyroid Graves’ disease, serum free triiodothyronine (FT3) levels significantly decreased immediately after surgery and were within the normal range by D1. Although LT4 was started on D1, FT3 levels continued to decline by D3 and remained low at W3 and M3. Serum FT4 levels followed a slower decline but remained within the normal range for M3. In patients with euthyroid Graves’ disease and those with thyroid nodules, hormone levels stayed within or around the reference range throughout the observation period. In conclusion, initiating LT4 on the day after surgery is safe and effective for maintaining thyroid function in patients with hyperthyroid Graves’ disease undergoing total thyroidectomy. These results could inform future guidelines, supporting earlier postoperative LT4 initiation.
No evidence-based standards exist regarding levothyroxine (LT4) replacement therapy initiation timing in patients with hyperthyroid Graves' disease undergoing total thyroidectomy. Although LT4 replacement from the first postoperative day has been the standard of care at our hospital, its clinical validity has not been thoroughly examined. This study investigated the perioperative kinetics of thyroid hormones to assess the safety and efficacy of early LT4 initiation. Thirty patients with Graves' disease (18 hyperthyroid and 12 euthyroid) and 12 with thyroid nodules who underwent total thyroidectomy were included. Blood samples were collected from each patient for thyroid hormone measurement on the day before surgery (D-1), 15 min after surgery (D0), at 8:00 am on days 1 (D1) and 3 (D3), and 3 weeks (W3) and 3 months (M3) after surgery. In 18 patients with hyperthyroid Graves' disease, serum free triiodothyronine (FT3) levels significantly decreased immediately after surgery and were within the normal range by D1. Although LT4 was started on D1, FT3 levels continued to decline by D3 and remained low at W3 and M3. Serum FT4 levels followed a slower decline but remained within the normal range for M3. In patients with euthyroid Graves' disease and those with thyroid nodules, hormone levels stayed within or around the reference range throughout the observation period. In conclusion, initiating LT4 on the day after surgery is safe and effective for maintaining thyroid function in patients with hyperthyroid Graves' disease undergoing total thyroidectomy. These results could inform future guidelines, supporting earlier postoperative LT4 initiation.No evidence-based standards exist regarding levothyroxine (LT4) replacement therapy initiation timing in patients with hyperthyroid Graves' disease undergoing total thyroidectomy. Although LT4 replacement from the first postoperative day has been the standard of care at our hospital, its clinical validity has not been thoroughly examined. This study investigated the perioperative kinetics of thyroid hormones to assess the safety and efficacy of early LT4 initiation. Thirty patients with Graves' disease (18 hyperthyroid and 12 euthyroid) and 12 with thyroid nodules who underwent total thyroidectomy were included. Blood samples were collected from each patient for thyroid hormone measurement on the day before surgery (D-1), 15 min after surgery (D0), at 8:00 am on days 1 (D1) and 3 (D3), and 3 weeks (W3) and 3 months (M3) after surgery. In 18 patients with hyperthyroid Graves' disease, serum free triiodothyronine (FT3) levels significantly decreased immediately after surgery and were within the normal range by D1. Although LT4 was started on D1, FT3 levels continued to decline by D3 and remained low at W3 and M3. Serum FT4 levels followed a slower decline but remained within the normal range for M3. In patients with euthyroid Graves' disease and those with thyroid nodules, hormone levels stayed within or around the reference range throughout the observation period. In conclusion, initiating LT4 on the day after surgery is safe and effective for maintaining thyroid function in patients with hyperthyroid Graves' disease undergoing total thyroidectomy. These results could inform future guidelines, supporting earlier postoperative LT4 initiation.
ArticleNumber EJ25-0009
Author Daisuke Tatsushima
Atsushi Yamaoka
Hiroyuki Yamashita
Takashi Fukuda
Hiroshi Takahashi
Seigo Tachibana
Yusuke Mori
Shinya Sato
Kento Katsuyama
Yuji Nagayama
Hisakazu Shindo
Misa Okamura
Author_xml – sequence: 1
  givenname: Yuji
  orcidid: 0000-0002-5058-9349
  surname: Nagayama
  fullname: Nagayama, Yuji
– sequence: 2
  givenname: Seigo
  orcidid: 0000-0003-4154-500X
  surname: Tachibana
  fullname: Tachibana, Seigo
– sequence: 3
  givenname: Takashi
  orcidid: 0009-0007-5846-8748
  surname: Fukuda
  fullname: Fukuda, Takashi
– sequence: 4
  givenname: Kento
  surname: Katsuyama
  fullname: Katsuyama, Kento
– sequence: 5
  givenname: Daisuke
  surname: Tatsushima
  fullname: Tatsushima, Daisuke
– sequence: 6
  givenname: Yusuke
  orcidid: 0009-0003-4297-134X
  surname: Mori
  fullname: Mori, Yusuke
– sequence: 7
  givenname: Hisakazu
  orcidid: 0000-0002-1424-620X
  surname: Shindo
  fullname: Shindo, Hisakazu
– sequence: 8
  givenname: Hiroshi
  orcidid: 0009-0005-0410-1399
  surname: Takahashi
  fullname: Takahashi, Hiroshi
– sequence: 9
  givenname: Misa
  surname: Okamura
  fullname: Okamura, Misa
– sequence: 10
  givenname: Atsushi
  surname: Yamaoka
  fullname: Yamaoka, Atsushi
– sequence: 11
  givenname: Shinya
  orcidid: 0000-0002-0761-6209
  surname: Sato
  fullname: Sato, Shinya
– sequence: 12
  givenname: Hiroyuki
  orcidid: 0009-0001-0805-8886
  surname: Yamashita
  fullname: Yamashita, Hiroyuki
BackLink https://cir.nii.ac.jp/crid/1390585116986227840$$DView record in CiNii
https://www.ncbi.nlm.nih.gov/pubmed/40139844$$D View this record in MEDLINE/PubMed
BookMark eNpdks1uEzEQgFeoiKaFB-CCVoIDly3-3bVPCFUhFFXiAjcky_bOJo42drCdiNx4jb5en4Td_IlyGUv2N9_Y47kqLnzwUBSvMbrBHDUfwLfBxuXN9CvhFUJIPismmDJRMc7QRTFBEotKSC4vi6uUlghRyhl9UVwyhKkUjE2Kn1Md-125DimHNUSd3RbKHrYhL3Yx_HYeSudddsNB8KXuMsQyh6z7cg-4FmwOq13ZhVjOot5CevzzULYugU7wsnje6T7Bq-N6Xfz4PP1--6W6_za7u_10X9m6ZrkipDbSUilbLYXpiMES1RozjiwHJgG6znRNTWqOdGs0aKENJdxIgcEyI-l1cXfwtkEv1Tq6lY47FbRT-40Q50rH7GwPihOKakNxU2PJxl7RrkFtY0SHrWhBDK6PB9d6Y1bQWvA56v6J9OmJdws1D1uFh2cgLEbD-6Mhhl8bSFmtXLLQ99pD2CRFsSCs4Yg3A_r2P3QZNtEPvVKU0OHjJGZooN78e6XzXU6_OAD4ANgYUorQnRGM1Dgp6jgpapwUNU7KkPPukOOdU9aNcbAhLjjGtRQ1IY3Y154dsGXKeg5n8amfJ3FDVDOGc4EzYRc6Dhj9C7lb2RU
Cites_doi 10.1097/SLA.0000000000003580
10.1186/s40463-018-0281-z
10.1067/msy.1998.91254
10.1172/JCI106835
10.1038/bmt.2012.244
10.1089/thy.2016.0229
10.1089/thy.1991.1.273
10.1001/jama.2023.19052
10.1089/thy.2022.0392
10.1210/en.2015-1848
10.7326/0003-4819-100-3-372
10.1210/jcem-23-11-1067
10.1007/s00268-020-05654-4
10.3803/EnM.2021.1198
10.1016/j.ijsu.2017.01.086
10.1210/jcem-41-2-354
10.3390/jcm11092416
10.1089/thy.2016.0456
10.1001/jama.299.7.769
10.1159/000490384
10.1089/thy.2019.0135
10.1210/jc.2007-0178
ContentType Journal Article
Copyright The Japan Endocrine Society
2025. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Japan Endocrine Society 2025
Copyright_xml – notice: The Japan Endocrine Society
– notice: 2025. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Japan Endocrine Society 2025
DBID RYH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7T5
7TK
8FD
FR3
H94
K9.
NAPCQ
P64
RC3
7X8
5PM
DOA
DOI 10.1507/endocrj.EJ25-0009
DatabaseName CiNii Complete
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Neurosciences Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Nursing & Allied Health Premium
Genetics Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic



Nursing & Allied Health Premium
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Nagayama et al
EISSN 1348-4540
EndPage 818
ExternalDocumentID oai_doaj_org_article_52306b317619413483f70d7b8f1c8de8
PMC12260188
40139844
10_1507_endocrj_EJ25_0009
article_endocrj_72_7_72_EJ25_0009_article_char_en
Genre Journal Article
GroupedDBID ---
.55
.GJ
29G
2WC
3O-
53G
5GY
5RE
AAEJM
AAFWJ
ACPRK
ADBBV
AENEX
AFPKN
AJJEV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BKOMP
CS3
DIK
DU5
E3Z
EBD
EBS
EJD
EMOBN
F5P
GROUPED_DOAJ
JMI
JSF
JSH
KQ8
MOJWN
OK1
OVT
P2P
RJT
RNS
RPM
RZJ
SV3
TKC
TR2
X7M
XSB
ZGI
ZXP
RYH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7T5
7TK
8FD
FR3
H94
K9.
NAPCQ
P64
RC3
7X8
5PM
ID FETCH-LOGICAL-c664t-226b9c399da98bf2b1906a1450c5e49eeffbf762650adbaea8ab325b981ec4b93
IEDL.DBID DOA
ISSN 0918-8959
1348-4540
IngestDate Wed Aug 27 00:56:57 EDT 2025
Thu Aug 21 18:22:32 EDT 2025
Wed Jul 02 05:12:32 EDT 2025
Fri Aug 15 06:10:53 EDT 2025
Fri Jul 18 01:41:12 EDT 2025
Thu Jul 10 08:31:32 EDT 2025
Thu Jun 26 23:51:28 EDT 2025
Wed Sep 03 06:30:41 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords Levothyroxine
Liothyronine
Graves’ disease
Hyperthyroidism
Total thyroidectomy
Language English
License https://creativecommons.org/licenses/by-nc-nd/4.0
This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c664t-226b9c399da98bf2b1906a1450c5e49eeffbf762650adbaea8ab325b981ec4b93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-5058-9349
0009-0003-4297-134X
0009-0007-5846-8748
0009-0005-0410-1399
0009-0001-0805-8886
0000-0003-4154-500X
0000-0002-1424-620X
0000-0002-0761-6209
OpenAccessLink https://doaj.org/article/52306b317619413483f70d7b8f1c8de8
PMID 40139844
PQID 3239599140
PQPubID 2048504
PageCount 6
ParticipantIDs doaj_primary_oai_doaj_org_article_52306b317619413483f70d7b8f1c8de8
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12260188
proquest_miscellaneous_3182475057
proquest_journals_3239599140
pubmed_primary_40139844
crossref_primary_10_1507_endocrj_EJ25_0009
nii_cinii_1390585116986227840
jstage_primary_article_endocrj_72_7_72_EJ25_0009_article_char_en
PublicationCentury 2000
PublicationDate 2025-01-01
PublicationDateYYYYMMDD 2025-01-01
PublicationDate_xml – month: 01
  year: 2025
  text: 2025-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Japan
PublicationPlace_xml – name: Japan
– name: Kyoto
PublicationTitle Endocrine Journal
PublicationTitleAlternate Endocr J
PublicationTitle_FL Endocr J
PublicationYear 2025
Publisher The Japan Endocrine Society
一般社団法人 日本内分泌学会
Japan Science and Technology Agency
Publisher_xml – name: The Japan Endocrine Society
– name: 一般社団法人 日本内分泌学会
– name: Japan Science and Technology Agency
References 15 Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48: 452–458.
23 Wiersinga WM (1991) Propranolol and thyroid hormone metabolism. Thyroid 1: 273–277.
5 Al Jassim A, Wallace T, Bouhabel S, Majdan A, Hier M, et al. (2018) A retrospective cohort study: do patients with graves’ disease need to be euthyroid prior to surgery? J Otolaryngol Head Neck Surg 47: 37.
7 Hermann M, Richter B, Roka R, Freissmuth M (1994) Thyroid surgery in untreated severe hyperthyroidism: perioperative kinetics of free thyroid hormones in the glandular venous effluent and peripheral blood. Surgery 115: 240–245.
16 Takamatsu J, Sugawara M, Kuma K, Kobayashi A, Matsuzuka F, et al. (1984) Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves’ disease. Ann Intern Med 100: 372–375.
14 Inomata K, Yamamoto A, Yukishita M, Adachi M, Yamashita H, et al. (2004) Fundamental and clinical evaluation of ECLusys FT3 II and thyroid function related tests by automated electrochemiluminescence immunoassay system Modular Analytics . Igaku to Yakugaku 51: 187–196 (In Japanese).
6 Fazendin J, Zmijewski P, Allahwasaya A, McLeod C, Akhund R, et al. (2023) Surgical treatment of hyperthyroidism can be performed safely before a euthyroid state is achieved. Thyroid 33: 691–696.
2 Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, et al. (2016) 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26: 1343–1421.
19 Jonklaas J, Davidson B, Bhagat S, Soldin SJ (2008) Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA 299: 769–777.
10 Nicoloff JT, Low JC, Dussault JH, Fisher DA (1972) Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. J Clin Invest 51: 473–483.
20 Senese N, Lechien JR, Poppe K, Rodriguez A, Dequanter D (2022) Changes in TSH, T4, T3 and thyroglobulin levels throughout total thyroidectomy. J Clin Med 11: 2416.
11 Ohba K, Leow MK, Singh BK, Sinha RA, Lesmana R, et al. (2016) Desensitization and incomplete recovery of hepatic target genes after chronic thyroid hormone treatment and withdrawal in male adult mice. Endocrinology 157: 1660–1672.
21 Hsieh LB, Yen TWF, Dream S, Patel D, Evans DB, et al. (2020) Perioperative management and outcomes of hyperthyroid patients unable to tolerate antithyroid drugs. World J Surg 44: 3770–3777.
8 Hermann M, Roka R, Richter B, Freissmuth M (1998) Early relapse after operation for Graves’ disease: postoperative hormone kinetics and outcome after subtotal, near-total, and total thyroidectomy. Surgery 124: 894–900.
9 Beckers C, Vandenschrieck HG, Devisscher M (1963) Peripheral metabolism of labeled thyroid hormones in goitrous patients from the Uele endemic (Republic of the Congo). J Clin Endocrinol Metab 23: 1067–1073.
18 Ito M, Kawasaki M, Danno H, Kohsaka K, Nakamura T, et al. (2019) Serum thyroid hormone balance in levothyroxine monotherapy-treated patients with atrophic thyroid after radioiodine treatment for Graves’ disease. Thyroid 29: 1364–1370.
12 Ohba K, Sinha RA, Singh BK, Iannucci LF, Zhou J, et al. (2017) Changes in Hepatic TRβ protein expression, lipogenic gene expression, and long-chain acylcarnitine levels during chronic hyperthyroidism and triiodothyronine withdrawal in a mouse model. Thyroid 27: 852–860.
13 Yang S, Zhou L, Lu Z, Ma B, Ji Q, et al. (2017) Systematic review with meta-analysis of intraoperative neuromonitoring during thyroidectomy. Int J Surg 39: 104–113.
24 Williams DE, Chopra IJ, Orgiazzi J, Solomon DH (1975) Acute effects of corticosteroids on thyroid activity in Graves’ disease. J Clin Endocrinol Metab 41: 354–361.
17 Laurberg P, Vestergaard H, Nielsen S, Christensen SE, Seefeldt T, et al. (2007) Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J Clin Endocrinol Metab 92: 2149–2156.
3 Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, et al. (2018) 2018 European Thyroid Association Guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J 7: 167–186.
4 Patel KN, Yip L, Lubitz CC, Grubbs EG, Miller BS, et al. (2020) The American Association of Endocrine Surgeons Guidelines for the definitive surgical management of thyroid disease in adults. Ann Surg 271: e21–e93.
22 Sabatino L, Vassalle C, Del Seppia C, Iervasi G (2021) Deiodinases and the three types of thyroid hormone deiodination reactions. Endocrinol Metab (Seoul) 36: 952–964.
1 Lee SY, Pearce EN (2023) Hyperthyroidism: a review. JAMA 330: 1472–1483.
11
22
12
23
13
24
14
15
16
17
18
19
1
2
3
4
5
6
7
8
9
20
10
21
References_xml – reference: 9 Beckers C, Vandenschrieck HG, Devisscher M (1963) Peripheral metabolism of labeled thyroid hormones in goitrous patients from the Uele endemic (Republic of the Congo). J Clin Endocrinol Metab 23: 1067–1073.
– reference: 14 Inomata K, Yamamoto A, Yukishita M, Adachi M, Yamashita H, et al. (2004) Fundamental and clinical evaluation of ECLusys FT3 II and thyroid function related tests by automated electrochemiluminescence immunoassay system Modular Analytics . Igaku to Yakugaku 51: 187–196 (In Japanese).
– reference: 1 Lee SY, Pearce EN (2023) Hyperthyroidism: a review. JAMA 330: 1472–1483.
– reference: 13 Yang S, Zhou L, Lu Z, Ma B, Ji Q, et al. (2017) Systematic review with meta-analysis of intraoperative neuromonitoring during thyroidectomy. Int J Surg 39: 104–113.
– reference: 19 Jonklaas J, Davidson B, Bhagat S, Soldin SJ (2008) Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA 299: 769–777.
– reference: 5 Al Jassim A, Wallace T, Bouhabel S, Majdan A, Hier M, et al. (2018) A retrospective cohort study: do patients with graves’ disease need to be euthyroid prior to surgery? J Otolaryngol Head Neck Surg 47: 37.
– reference: 22 Sabatino L, Vassalle C, Del Seppia C, Iervasi G (2021) Deiodinases and the three types of thyroid hormone deiodination reactions. Endocrinol Metab (Seoul) 36: 952–964.
– reference: 6 Fazendin J, Zmijewski P, Allahwasaya A, McLeod C, Akhund R, et al. (2023) Surgical treatment of hyperthyroidism can be performed safely before a euthyroid state is achieved. Thyroid 33: 691–696.
– reference: 21 Hsieh LB, Yen TWF, Dream S, Patel D, Evans DB, et al. (2020) Perioperative management and outcomes of hyperthyroid patients unable to tolerate antithyroid drugs. World J Surg 44: 3770–3777.
– reference: 24 Williams DE, Chopra IJ, Orgiazzi J, Solomon DH (1975) Acute effects of corticosteroids on thyroid activity in Graves’ disease. J Clin Endocrinol Metab 41: 354–361.
– reference: 7 Hermann M, Richter B, Roka R, Freissmuth M (1994) Thyroid surgery in untreated severe hyperthyroidism: perioperative kinetics of free thyroid hormones in the glandular venous effluent and peripheral blood. Surgery 115: 240–245.
– reference: 23 Wiersinga WM (1991) Propranolol and thyroid hormone metabolism. Thyroid 1: 273–277.
– reference: 10 Nicoloff JT, Low JC, Dussault JH, Fisher DA (1972) Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. J Clin Invest 51: 473–483.
– reference: 3 Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, et al. (2018) 2018 European Thyroid Association Guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J 7: 167–186.
– reference: 18 Ito M, Kawasaki M, Danno H, Kohsaka K, Nakamura T, et al. (2019) Serum thyroid hormone balance in levothyroxine monotherapy-treated patients with atrophic thyroid after radioiodine treatment for Graves’ disease. Thyroid 29: 1364–1370.
– reference: 17 Laurberg P, Vestergaard H, Nielsen S, Christensen SE, Seefeldt T, et al. (2007) Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J Clin Endocrinol Metab 92: 2149–2156.
– reference: 20 Senese N, Lechien JR, Poppe K, Rodriguez A, Dequanter D (2022) Changes in TSH, T4, T3 and thyroglobulin levels throughout total thyroidectomy. J Clin Med 11: 2416.
– reference: 4 Patel KN, Yip L, Lubitz CC, Grubbs EG, Miller BS, et al. (2020) The American Association of Endocrine Surgeons Guidelines for the definitive surgical management of thyroid disease in adults. Ann Surg 271: e21–e93.
– reference: 11 Ohba K, Leow MK, Singh BK, Sinha RA, Lesmana R, et al. (2016) Desensitization and incomplete recovery of hepatic target genes after chronic thyroid hormone treatment and withdrawal in male adult mice. Endocrinology 157: 1660–1672.
– reference: 16 Takamatsu J, Sugawara M, Kuma K, Kobayashi A, Matsuzuka F, et al. (1984) Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves’ disease. Ann Intern Med 100: 372–375.
– reference: 15 Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48: 452–458.
– reference: 8 Hermann M, Roka R, Richter B, Freissmuth M (1998) Early relapse after operation for Graves’ disease: postoperative hormone kinetics and outcome after subtotal, near-total, and total thyroidectomy. Surgery 124: 894–900.
– reference: 12 Ohba K, Sinha RA, Singh BK, Iannucci LF, Zhou J, et al. (2017) Changes in Hepatic TRβ protein expression, lipogenic gene expression, and long-chain acylcarnitine levels during chronic hyperthyroidism and triiodothyronine withdrawal in a mouse model. Thyroid 27: 852–860.
– reference: 2 Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, et al. (2016) 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26: 1343–1421.
– ident: 4
  doi: 10.1097/SLA.0000000000003580
– ident: 5
  doi: 10.1186/s40463-018-0281-z
– ident: 8
  doi: 10.1067/msy.1998.91254
– ident: 10
  doi: 10.1172/JCI106835
– ident: 15
  doi: 10.1038/bmt.2012.244
– ident: 2
  doi: 10.1089/thy.2016.0229
– ident: 23
  doi: 10.1089/thy.1991.1.273
– ident: 1
  doi: 10.1001/jama.2023.19052
– ident: 6
  doi: 10.1089/thy.2022.0392
– ident: 11
  doi: 10.1210/en.2015-1848
– ident: 16
  doi: 10.7326/0003-4819-100-3-372
– ident: 9
  doi: 10.1210/jcem-23-11-1067
– ident: 14
– ident: 21
  doi: 10.1007/s00268-020-05654-4
– ident: 22
  doi: 10.3803/EnM.2021.1198
– ident: 13
  doi: 10.1016/j.ijsu.2017.01.086
– ident: 24
  doi: 10.1210/jcem-41-2-354
– ident: 20
  doi: 10.3390/jcm11092416
– ident: 12
  doi: 10.1089/thy.2016.0456
– ident: 19
  doi: 10.1001/jama.299.7.769
– ident: 3
  doi: 10.1159/000490384
– ident: 7
– ident: 18
  doi: 10.1089/thy.2019.0135
– ident: 17
  doi: 10.1210/jc.2007-0178
SSID ssj0033543
Score 2.3988056
Snippet No evidence-based standards exist regarding levothyroxine (LT4) replacement therapy initiation timing in patients with hyperthyroid Graves’ disease undergoing...
No evidence-based standards exist regarding levothyroxine (LT4) replacement therapy initiation timing in patients with hyperthyroid Graves' disease undergoing...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
nii
jstage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 813
SubjectTerms Adult
Aged
Female
Graves disease
Graves Disease - blood
Graves Disease - drug therapy
Graves Disease - surgery
Hormone Replacement Therapy - methods
Humans
Hyperthyroidism
Levothyroxine
Liothyronine
Male
Middle Aged
Nodules
Original
Patients
Postoperative Care - methods
Postoperative Period
Surgery
Thyroid gland
Thyroid hormones
Thyroid Nodule - blood
Thyroid Nodule - surgery
Thyroidectomy
Thyroxine
Thyroxine - administration & dosage
Thyroxine - blood
Thyroxine - therapeutic use
Total thyroidectomy
Treatment Outcome
Triiodothyronine
Triiodothyronine - blood
Young Adult
Title Early postoperative levothyroxine initiation after total thyroidectomy for Graves’ disease
URI https://www.jstage.jst.go.jp/article/endocrj/72/7/72_EJ25-0009/_article/-char/en
https://cir.nii.ac.jp/crid/1390585116986227840
https://www.ncbi.nlm.nih.gov/pubmed/40139844
https://www.proquest.com/docview/3239599140
https://www.proquest.com/docview/3182475057
https://pubmed.ncbi.nlm.nih.gov/PMC12260188
https://doaj.org/article/52306b317619413483f70d7b8f1c8de8
Volume 72
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Endocrine Journal, 2025, Vol.72(7), pp.813-818
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagB8QFUZ6BtjISJ6TQxK_YtxbUUlUqJyr1gGTZiS1SlWS13aL2xt_g7_FLOuM81EVIXLhE0XqySeazM9947BlC3tZNKaJWZR7B2ORCBZUb71lujBM6CB5VwL3DJ5_V0ak4PpNnd0p94ZqwIT3woLhdnLVUHqwcutslF5rHqmgqr2NZ6yakbb5g8yZnavgGcy4FH2OYQHh2Q9f09fL8_cExk7iP2qxZoZSsHyzQOfAx3Gh_v2vbvxHOP9dN3jFEh4_Jo5FB0v3hyTfJvdA9IQ9Oxhj5U_I15SymC8yYsQhDYm96EX4gJMv-GmRoiyuGEiQ01Qinqx44OE0CbYPz-N9vKLBZ-gmLE13-_vmLjoGcZ-T08ODLx6N8rKGQ10qJVQ7sypsaWEjjjPaReSAAypVCFrUMwoQQo4_wQQSi5hrvgtPOcya90WWohTf8Odno-i68JFRG74tKRV6wKLQTTsIJujsYmjOeZ-TdpFO7GFJlWHQxAAA7AmARAIx3m4x8QK3PgpjlOv0A2NsRe_sv7DOyN2A2_8105XS_itkKD_N9Zwnc1AZiGdkGtC0ABEd4jQLDpKUy4OhhSLbIyNbUD-w4ui8tZ9xIINbY_GZuhnGJwRbXhf4KZMBxExW6fxl5MXSb-SnRpzVaiIzotQ61po31lq79lnJ_lwxzwGn96n_o7zV5yLCccZpR2iIbq-VV2AaOtfI7aTjtpMmvW-YtJps
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+postoperative+levothyroxine+initiation+after+total+thyroidectomy+for+Graves%E2%80%99+disease&rft.jtitle=Endocrine+journal&rft.au=Nagayama%2C+Yuji&rft.au=Tachibana%2C+Seigo&rft.au=Fukuda%2C+Takashi&rft.au=Katsuyama%2C+Kento&rft.date=2025-01-01&rft.pub=Japan+Science+and+Technology+Agency&rft.issn=0918-8959&rft.eissn=1348-4540&rft.volume=72&rft.issue=7&rft_id=info:doi/10.1507%2Fendocrj.EJ25-0009&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-8959&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-8959&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-8959&client=summon